Benefits from sustained virologic response to pegylated interferon plus ribavirin in HIV/hepatitis C virus-coinfected patients with compensated cirrhosis

Clinical Infectious Diseases

Volumn 56, Issue 11, 2013, Pages 1646-1653

  Mira, José A ^a,b   Rivero Juárez, Antonio ^c,d   López Cortés, Luis F ^b,d   Girón González, José A ^e   Téllez, Francisco ^f   Santos Gil, Ignacio De Los ^g   MacÍas, Juan ^a,b   Merino, Dolores ^h   Márquez, Manuel ⁱ   Ríos Villegas, María J ^j   Gea, Isabel ^k   Merchante, Nicolás ^a,b   Rivero, Antonio ^b,c   Torres Cornejo, Almudena ^b,d   Pineda, Juan A ^a,b  

^a HOSPITAL UNIVERSITARIO DE VALME   (Spain)

^b Instituto de Biomedicina de Sevilla   (Spain)

^c HOSPITAL UNIVERSITARIO REINA SOFÍA   (Spain)

^d HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^e HOSPITAL UNIVERSITARIO PUERTA DEL MAR   (Spain)

^f Hospital de la Linea de la Concepcion   (Spain)

^g HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

^h Hospital de Huelva   (Spain)

ⁱ HOSPITAL UNIVERSITARIO VIRGEN DE LA VICTORIA   (Spain)

^j HOSPITAL UNIVERSITARIO VIRGEN MACARENA   (Spain)

^k Unidad de Enfermedades Infecciosas   (Spain)

more..

Author keywords

cirrhosis; HCV; HIV; liver decompensation; sustained virologic response

Indexed keywords

PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RIBAVIRIN;

ANTIVIRAL THERAPY; ARTICLE; CAUSE OF DEATH; CD4 LYMPHOCYTE COUNT; COHORT ANALYSIS; CONTROLLED STUDY; DECOMPENSATED LIVER CIRRHOSIS; FEMALE; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVER BIOPSY; LIVER CIRRHOSIS; LIVER FAILURE; MAJOR CLINICAL STUDY; MALE; MIXED INFECTION; MORTALITY; OUTCOME ASSESSMENT; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; SCORING SYSTEM; TREATMENT DURATION; TREATMENT RESPONSE;

CIRRHOSIS; HCV; HIV; LIVER DECOMPENSATION; SUSTAINED VIROLOGIC RESPONSE;

ADULT; ANTIVIRAL AGENTS; FEMALE; HEPACIVIRUS; HEPATITIS C; HIV INFECTIONS; HUMANS; INTERFERON-ALPHA; KAPLAN-MEIER ESTIMATE; LIVER CIRRHOSIS; LIVER FAILURE; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; POLYETHYLENE GLYCOLS; PROSPECTIVE STUDIES; RECOMBINANT PROTEINS; RIBAVIRIN;

EID: 84877285315     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cit103     Document Type: Article

References (26)

1. Deng L, Gui X, Zhang YX, Gao SC, Yang RR. Impact of human immunodeficiency virus infection on the course of hepatitis C virus infection: a meta-analysis. World J Gastroenterol 2009; 15:996-1003.
2. Antiretroviral Therapy Cohort Collaboration. Causes of death in HIV-1-infected patients treated with antiretroviral therapy 1996-2006: collaborative analysis of 13 HIV cohort studies. Clin Infect Dis 2010; 50: 1387-96.
3. Graham CS, Baden LR, Yu E, et al. Influence of human immunodeficiency virus infection on the course of hepatitis C virus infection: a meta-analysis. Clin Infect Dis 2001; 33:562-9.
4. Benhamou Y, Bochet M, Di Martino V, et al. Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients. The Multivirc Group. Hepatology 1999; 30:1054-8.
5. Mira JA, García-Rey S, Rivero A, et al. Response to pegylated interfer-on plus ribavirin among HIV/HCV-coinfected patients with compensated liver cirrhosis. Clin Infec Dis 2012; 55:1719-26.
6. Martín-Carbonero L, Tuma P, Vispo E, et al. Treatment of chronic hepatitis C in HIV-infected patients with compensated liver cirrhosis. J Viral Hepat 2011; 18:542-8.
7. Pineda JA, Romero-Gómez M, Díaz-García F, et al. HIV coinfection shortens the survival of patients with hepatitis C virus-related decom-pensated cirrhosis. Hepatology 2005; 41:779-89.
8. Veldt BJ, Heathcote EJ, Wedemeyer H, et al. Sustained virologic response and clinical outcomes in patients with chronic hepatitis C and advanced fibrosis. Ann Intern Med 2007; 147:677-84.
9. Backus LI, Boothroyd DB, Phillips BR, Belperio P, Halloran J, Male LA. A sustained virologic response reduces risk of all-cause mortality in patients with hepatitis C. Clin Gastroenterol Hepatol 2011; 9: 509-16.
10. Cardoso A, Moucari R, Figueiredo-Mendes C, et al. Impact of pegin-terferon and ribavirin therapy on hepatocellular carcinoma: incidence and survival in hepatitis C patients with advanced fibrosis. J Hepatol 2010; 52:652-7.
11. Fernández-Rodríguez CM, Alonso S, Martínez SM, et al. Peginterferon plus ribavirin and sustained virological response in HCV-related cirrhosis: outcomes and factors predicting response. Am J Gastroenterol 2010; 105:2164-72.
12. Cheinquer N, Cheinquer H, Wolff FH, Coelho-Borges S. Effect of sustained virologic response on the incidence of hepatocellular carcinoma in patients with HCV cirrhosis. Braz J Infect Dis 2010; 14: 457-61.
13. Berenguer J, Alvarez-Pellicer J, Martín PM, et al. Sustained virological response to interferon plus ribavirin reduces liver-related complications and mortality in patients coinfected with human immunodeficiency virus and hepatitis C virus. Hepatology 2009; 50:407-13.
14. Scheuer PJ. Classification of chronic viral hepatitis: a need for reassessment. J Hepatol 1991; 13:372-4.
15. Vergara S, Macías J, Rivero A, et al. The use of transient elastometry for assessing liver fibrosis in patients with HIV and hepatitis C virus coinfection. Clin Infect Dis 2007; 45:969-74.
16. Merchante N, Jiménez-Sáez M, Pineda JA. Management of HCV-related end-stage liver disease in HIV-coinfected patients. AIDS Rev 2007; 9:131-9.
17. Merchante N, Rivero-Juárez A, Téllez F, et al. Liver stiffness predicts clinical outcome in HIV/HCV-coinfected patients with compensated liver cirrhosis. Hepatology 2012; 56:228-38.
18. Pineda JA, Aguilar-Guisado M, Rivero A, et al. Natural history of compensated hepatitis C virus-related cirrhosis in HIV-infected patients. Clin Infect Dis 2009; 49:1274-82.
19. Limketkai BN, Mehta SH, Suteliffe CG, et al. Relationship of liver disease stage and antiviral therapy with liver-related events and death in adults coinfected with HIV/HCV. JAMA 2012; 308:370-8.
20. Merchante N, Merino E, López-Aldeguer J, et al. Increasing incidence of hepatocellular carcinoma in HIV-infected patients in Spain. Clin Infect Dis 2012; 56:143-50.
21. Jacobson IM, McHutchison JG, Dusheiko G, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011; 364:2405-16.
22. Poordad F, McCone J Jr, Bacon BR, et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011; 364: 1195-206.
23. Dieterich D, Soriano V, Sherman K, et al. Telaprevir in combination with pegylated interferon-alpha-2a plus ribavirin in HCV/HIV-coinfected patients: a 24-week treatment interim analysis. In: 19th Conference on Retroviruses and Opportunistic Infections. Seattle, WA, 5-8 March 2012. Abstract 46.
24. Sulkowski MS, Pol S, Cooper C, et al. Boceprevir plus peginterferon/ribavirin for the treatment of HCV/HIV co-infected patients: end of treatment (week 48) interim results. In: 19th Conference on Retrovi-ruses and Opportunistic Infections. Seattle, WA, 5-8 March 2012. Abstract 47.
25. Sulkowski MS. Hepatitis C virus-human immunodeficiency virus coinfection. Liver Int 2012; 32(suppl 1):129-34.
26. Piroth L. Direct-acting antivirals for hepatitis C virus infections in patients co-infected with human immunodeficiency virus. Clin Res Hepatol Gastroenterol 2011; 35:75-83.